The FDA has approved an update to the prescribing information for Merck‘s PAH treatment Winrevair (sotatercept-csrk).
Pulmonary hypertension treatment can help slow disease progression, ease symptoms, and improve quality of life for people with the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback